BiTE Antibodies (Tarlatamab)

Type: drug

Status: FDA Approved

Developer: Amgen

Breakthrough Summary

No summary available.

Mechanism of Action

Bispecific T-cell engager redirecting immune cells to tumor

Year: 2024